Lazard Asset Management
GH icon

Lazard Asset Management’s Guardant Health GH Stock Holding History

Lazard Asset Management’s Portfolio GH Stock Details GH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.26M Sell
24,419
-6,166
-20% -$619K ﹤0.01% 834
2025
Q4 		$3.12M Sell
30,585
-19,925
-39% -$1.78M 0.01% 698
2025
Q3 		$3.16M Buy
50,510
+20,855
+70% +$1.13M ﹤0.01% 723
2025
Q2 		$1.54M Sell
29,655
-1,151
-4% -$51.4K ﹤0.01% 1106
2025
Q1 		$1.31M Sell
30,806
-18,825
-38% -$812K ﹤0.01% 1107
2024
Q4 		$1.52M Sell
49,631
-69,620
-58% -$1.96M ﹤0.01% 978
2024
Q3 		$2.73M Sell
119,251
-17,018
-12% -$482K ﹤0.01% 795
2024
Q2 		$3.94M Sell
136,269
-1,498
-1% -$34.9K ﹤0.01% 737
2024
Q1 		$2.84M Sell
137,767
-12,370
-8% -$265K ﹤0.01% 784
2023
Q4 		$4.06M Sell
150,137
-6,154
-4% -$161K 0.01% 723
2023
Q3 		$4.63M Sell
156,291
-40,330
-21% -$1.42M 0.01% 709
2023
Q2 		$7.04M Sell
196,621
-197
-0.1% -$5.66K 0.01% 629
2023
Q1 		$4.61M Buy
196,818
+42,751
+28% +$1.22M 0.01% 743
2022
Q4 		$4.19M Sell
154,067
-64,244
-29% -$2.94M 0.01% 757
2022
Q3 		$11.8M Buy
218,311
+8,183
+4% +$420K 0.02% 537
2022
Q2 		$8.48M Buy
210,128
+99,893
+91% +$4.95M 0.01% 620
2022
Q1 		$7.3M Buy
110,235
+26,217
+31% +$1.79M 0.01% 684
2021
Q4 		$8.4M Buy
84,018
+43,054
+105% +$4.45M 0.01% 676
2021
Q3 		$5.12M Buy
40,964
+7,729
+23% +$918K 0.01% 759
2021
Q2 		$4.13M Buy
33,235
+32,717
+6,316% +$4.4M ﹤0.01% 749
2021
Q1 		$79K Sell
518
-68
-12% -$10.3K ﹤0.01% 1261
2020
Q4 		$75K Buy
+586
New +$67.4K ﹤0.01% 1261
2020
Q3 		– Sell
-47
Closed -$3K – 1654
2020
Q2 		$3K Buy
+47
New +$3.79K ﹤0.01% 1543

Other funds holding GH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lazard Asset Management's GH Position: Q1 2026 in Review

Lazard Asset Management reduced its Guardant Health (GH) stake by 20% in Q1 2026, selling an estimated $619K and leaving 24,419 shares worth $2.26M. The position accounts for ﹤0.01% of the portfolio, ranked #834.

Lazard Asset Management first reported a position in GH in Q2 2020 and has held it in 23 quarters since. The position peaked at $11.8M in Q3 2022. 481 funds tracked by Wall St. Rank hold GH as of Q1 2026.

  • Lazard Asset Management held 24,419 shares of Guardant Health worth $2.26M as of Q1 2026.
  • Lazard Asset Management sold 6,166 Guardant Health shares in Q1 2026, an estimated $619K.
  • Guardant Health made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #834 holding.
  • Lazard Asset Management first reported a position in Guardant Health in Q2 2020 and has held it in 23 quarters since.
  • Lazard Asset Management's Guardant Health position peaked at $11.8M in Q3 2022.
  • 481 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.